| __timestamp | Bio-Techne Corporation | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 9335772 |
| Thursday, January 1, 2015 | 144969000 | 999000 |
| Friday, January 1, 2016 | 162364000 | 978000 |
| Sunday, January 1, 2017 | 188462000 | 952000 |
| Monday, January 1, 2018 | 210850000 | 956000 |
| Tuesday, January 1, 2019 | 240515000 | 8122999 |
| Wednesday, January 1, 2020 | 255497000 | 8712000 |
| Friday, January 1, 2021 | 298182000 | 13980000 |
| Saturday, January 1, 2022 | 349103000 | 21135000 |
| Sunday, January 1, 2023 | 366887000 | 10755000 |
| Monday, January 1, 2024 | 389335000 |
In pursuit of knowledge
In the ever-evolving biotech industry, understanding cost dynamics is crucial. Bio-Techne Corporation, a leader in the field, has seen its cost of revenue grow by approximately 266% from 2014 to 2023. This reflects the company's expansion and increased production capabilities. In contrast, Iovance Biotherapeutics, Inc., a smaller player, experienced a more volatile trend, with costs peaking in 2022 at over 21 million before dropping by nearly 50% in 2023. This fluctuation highlights the challenges faced by emerging biotech firms in managing production costs. Notably, data for 2024 is incomplete, indicating potential shifts in the market landscape. As the biotech sector continues to innovate, monitoring these financial trends offers valuable insights into the operational strategies of key industry players.
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Bio-Techne Corporation
Cost of Revenue: Key Insights for GSK plc and Iovance Biotherapeutics, Inc.
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Bio-Techne Corporation vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bio-Techne Corporation vs Perrigo Company plc
Bio-Techne Corporation vs Iovance Biotherapeutics, Inc.: Strategic Focus on R&D Spending
Bio-Techne Corporation vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Catalent, Inc. vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: CRISPR Therapeutics AG and Iovance Biotherapeutics, Inc.
Cost of Revenue: Key Insights for Xenon Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc.